A Double-Edged Sword—Cardiovascular Concerns of Potential Anti-COVID-19 Drugs

Wen Liang Yu, Han Siong Toh, Chia Te Liao, Wei Ting Chang

研究成果: 雜誌貢獻回顧型文獻同行評審

2 引文 斯高帕斯(Scopus)

摘要

Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including the cardiovascular system. Most importantly, in addition to the direct injury from the virus per se, the subsequent cytokine storm, an overproduction of immune cells and their activating compounds, causes devastating damage. To date, emerging anti-SARS-CoV-2 treatments are warranted to control epidemics. Several candidate drugs have been screened and are currently under investigation. These primarily include antiviral regimens and immunomodulatory regimens. However, beyond the anti-SARS-CoV-2 effects, these drugs may also have risks to the cardiovascular system, especially altering cardiac conduction. Herein, we review the cardiovascular risks of potential anti-COVID-19 drugs.
原文英語
頁(從 - 到)205-214
頁數10
期刊Cardiovascular Drugs and Therapy
35
發行號2
DOIs
出版狀態已發佈 - 四月 2021

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

指紋 深入研究「A Double-Edged Sword—Cardiovascular Concerns of Potential Anti-COVID-19 Drugs」主題。共同形成了獨特的指紋。

引用此